Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Bookbuild, announced on 5 February 2025, is now closed.
Verona Pharma plc (LON:VRP) Positive Top-line Data in 4 Week Phase 2b COPD Study.
Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function